Stock cytrx
During the day the stock fluctuated 14.78% from a day low at $0.27 to a day high of $0.31. Quick summary: 30 day high of the CYTR stock price was $0.32 and low was $0.23. 90 day high was $0.40 and low was $0.21. 52 week high for CytRx Corporation - $0.78 and low - $0.21. CYTR - CytRx Corp. Basic Chart, CytRx's stock plunges 70% premarket after disappointing cancer study data released late Monday MarketWatch. Monday, July 11, 2016. Find real-time CYTR - CytRx Corp stock quotes, company profile, news and forecasts from CNN Business. CytRx Corp. (OTC:CYTR) has 12 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,011,180 shares.
31 Jul 2017 CytRx maintains the compound's potential, pointing to data showing that CytRx also gave NantCell a warrant to buy up to 3 million shares of
HAE Law, LLP, has commenced a lawsuit against CytRx Corporation (Nasdaq: CYTR) for alleged violations of the federal securities laws and other violations. Call 619-342-8000. On July 28, CytRx’s stock jumped by over 40% following the announcement that a subsidiary of billionaire Patrick Soon-Shiong’s NantWorks, NantCell, had acquired $13 million worth of CytRx’s stock at $1.10 per share and agreed to invest up… CytRx has received the first $25 million of financing under the loan and security agreement. The proceeds will be used for pre-commercialization and manufacturing activities for aldoxorubicin, clinical development, and general corporate… Galena Biopharma (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. TroyGould represented CytRx Corporation (Nasdaq: CYTX) in connection with its $8.1 million registered direct offering of shares of common stock and newly
View CytRx Corporation CYTR investment & stock information. Get the latest CytRx Corporation CYTR detailed stock quotes, stock data, Real-Time ECN, charts, stats and
Subsequent to this contribution, CytRx owns approximately 85% of the outstanding stock of RXi, with the remainder owned by RXi's anticipated scientific advisory team. RXi is a "pure play" RNAi company dedicated to developing proprietary… Business Contracts, Corporate and Legal Forms, Agreements, Laws, Statutes & Codes, Jurisprudence - Lex Bibliotheca. We think these 11 Nasdaq penny stocks priced under $5, with average daily volume over 3 mil and beta over 1.5, have solid prospects in 2019. CytRx Corp. (Nasdaq:CYTR) shares slumped more than 60% to touch a new 52-week low in.. The stock recorded a trading volume of 4.48 million shares. The Company’s shares have surged 21.72% in the last month, 68.19% over the previous three months, and 78.72% since the start of this year.
CytRx Corporation is a biopharmaceutical company with expertise in discovering and developing new therapeutics to treat patients with high unmet needs. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.
29 Nov 2019 Get breaking news and analysis on CytRx Corporation (CYTR) stock, price quote and chart, trading and investing tools. Researching CytRx (OTCMKTS:CYTR) stock? View CYTR's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at I've been backing the truck up to buy more CYTR on this recent weakness. I've drilled down pretty deep on the recent Stage IIb trial results and am fully View the latest CytRx Corp. (CYTR) stock price, news, historical charts, analyst ratings and financial information from WSJ.
20 Mar 2014 Within days of the article's publication, CytRx's stock rose nearly 50% to $6.90. Last week, a class-action suit was filed against CytRx, its CEO
Business Contracts, Corporate and Legal Forms, Agreements, Laws, Statutes & Codes, Jurisprudence - Lex Bibliotheca. We think these 11 Nasdaq penny stocks priced under $5, with average daily volume over 3 mil and beta over 1.5, have solid prospects in 2019. CytRx Corp. (Nasdaq:CYTR) shares slumped more than 60% to touch a new 52-week low in.. The stock recorded a trading volume of 4.48 million shares. The Company’s shares have surged 21.72% in the last month, 68.19% over the previous three months, and 78.72% since the start of this year.
These returns cover a period from January 1, 1988 through December 2, 2019. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. CytRx Corporation - Research Reports by Finpedia. 11-16 finpedia.co CytRx Corporation (CYTR) is a biopharmaceutical company specializing in oncology. Its focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. During the day the stock fluctuated 14.78% from a day low at $0.27 to a day high of $0.31. Quick summary: 30 day high of the CYTR stock price was $0.32 and low was $0.23. 90 day high was $0.40 and low was $0.21. 52 week high for CytRx Corporation - $0.78 and low - $0.21. CYTR - CytRx Corp. Basic Chart, CytRx's stock plunges 70% premarket after disappointing cancer study data released late Monday MarketWatch. Monday, July 11, 2016.